本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
BEIJING, June 20, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it is amending the effective date for the previously announced plan for an ADS ratio change. The Company previously planned to change the ratio of the American depositary shares ("ADSs") to its Class A ordinary shares from thirteen (13) ADSs representing ten (10) Class A ordinary shares to one (1) ADS representing fifteen (15) Class A ordinary shares, with the change originally scheduled to take effect at the open of trading on June 30, 2025 (U.S. Eastern Time). Following further consideration, the Company has decided to take additional time to finalize preparations for the ADS ratio change. An updated timeline will be announced once it becomes available. For the Company's ADS holders, the ADS ratio change will result in an effect equivalent to a proportional reverse ADS split. There will be no change to the Company's Class A ordinary shares. ADS holders of record on the effective date will not be required to take any action in connection with the ADS ratio change. The exchange of then-held (old) ADSs for new ADS will occur automatically with the then-held ADSs being cancelled and new ADSs being issued by the depositary bank. The ADSs will continue to be traded on Nasdaq under the symbol "SY." No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than a proportional price based on ADS price before the change. About So-Young International Inc. So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law. For more information, please contact: So-Young Investor RelationsMs. Mona QiaoPhone: +86-10-8790-2012E-mail: ir@soyoung.com Christensen In ChinaMs. Charlie ChiPhone: +86-10-5900-1548E-mail: charlie.chi@christensencomms.com In USMs. Linda BergkampPhone: +1-480-614-3004Email: linda.bergkamp@christensencomms.com
The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+ This year marks the 30-year anniversary since the first adult cochlear implant surgery in mainland China which took place in 1995. Nearly 10 million people in China are suffering from severe to profound hearing loss, among whom only 1% are treated with cochlear implant. BOAO, China, June 20, 2025 /PRNewswire/ -- Cochlear, the global leader in implantable hearing solutions, today launched the Cochlear™ Nucleus® Nexa™ System – the world's first and only smart cochlear implant system.1+ Xinyu Li, General Manager, Greater China, Cochlear, explains the next generation technology has completely reimagined the internal components of the hearing device: "There are more than 10 years of research and development advancements built into the new Nucleus Nexa System. The System is powered by the new state-of-the-art chipset - the first update to any implant's internal chipset across the cochlear implant industry in almost 20 years. The new chipset utilises advanced processing, upgradeable firmware and onboard memory to drive the 'smarts' of the system and allows the implant to do many things that conventional cochlear implants are simply unable to do. This latest release represents a significant step forward in technology not just in our industry but importantly for people in China living with hearing loss." "We estimate there are tens of millions of people in China who could benefit from a cochlear implant. Thirty years since the very first cochlear implant surgery in China took place, we are incredibly proud to offer the new Nexa System in the Boao Lecheng International Medical Tourism Pilot Zone. We hope the Bo'ao pilot zone can be the door for Chinese people with hearing loss to access the latest product with innovative technology. In addition, we hope this accelerates the new product approval in the mainland market through the clinical evidence collection and professional capability development in the pilot zone," added Mr Li. The groundbreaking Nucleus Nexa System offers the world's first hearing implant solution with upgradeable implant firmware, revolutionising the way people with hearing loss can access future technology. 1+ Conventional cochlear implants available today can only access future innovation by upgrading their sound processor. With the Nucleus Nexa System this limitation is removed. People with a Nucleus Nexa System will be able to experience new features and advancements, via both updates to the firmware in their smart implant and upgrades to their sound processor over time. Jan Janssen, Chief Technology Officer at Cochlear, likens the Nucleus Nexa Implant to a smartphone for hearing: "This is the first cochlear implant in the world with its own firmware, meaning users can upgrade to new features and innovations throughout their lifetime. Just like a smartphone receives a firmware update, now people with a cochlear implant can stay connected to the latest technology updates seamlessly today and well into the future." The Nucleus® Nexa™ System is the also the first implant with built-in memory, allowing the personalised hearing settings (MAPs) of the user to be securely stored directly in their Nexa implant.[1] This innovation ensures users can seamlessly transfer their settings to a new Nucleus Nexa Sound Processor if their current one is lost or damaged. "The Nucleus Nexa System comes with a distinct advantage – it is the world's first cochlear implant with built-in memory, allowing user's personalised hearing settings (MAPS) to be stored securely in the implant. This advancement brings a greater level of personalisation to the hearing implant and offers unmatched convenience and efficiency." "Previously, if a user misplaced or damaged their sound processor, they would need to visit a clinic to obtain a replacement sound processor. This replacement device would need to be programmed with the user's personalised hearing settings in the clinic by a cochlear implant professional, taking valuable time from both the professional and the user. With the brand-new 'Smart Sync' feature, the user simply needs to pick-up or receive a "blank" Nexa sound processor and the personalised settings are automatically copied to the replacement sound processor allowing a person to hear with their cochlear implant again in a matter of seconds," explained Janssen. To make hearing easier, the Nucleus Nexa System intuitively responds to changing needs throughout each day.[1, 3-5] It can automatically adjust listening settings to help people hear more clearly.[1] The Nexa implant also features a new gold coil and new RF Link technology with dynamic power management. This facilitates more efficient power and data transfer between the sound processor and the implant and automatically maximize battery life for each user.# Stu Sayers, President of Asia Pacific & Latin America at Cochlear, explained the introduction of the Nexa System is timely given it coincides with a significant milestone for the business: "We have a proud history in China, and it is fitting that in 2025, the year we celebrate 30 years since the first cochlear implant surgery in China, we are introducing this next generation technology. Our innovative mindset and lifetime commitment to the thousands of people in China and around the world who rely on our products to hear is what sets us apart. We continue to break new ground with our products and services, driven by our passion to make a remarkable impact on the lives of people living with hearing loss." "The Nucleus Nexa System combines 40+ years of proven reliability of our trusted implants and technology leadership, with the new cutting-edge chipset packed with innovative features. With onboard diagnostics that monitor system performance to ensure optimal hearing, it reduces the burden on users and carers, setting a new standard in implantable hearing technology," added Mr Janssen. Cochlear has provided more than 850,000 hearing implants to people around the world and the company's implants have a proven track record of reliability over 40 years which is one of many reasons people choose a Cochlear hearing solution more than any other brand.[6-7] In 2024 Cochlear was named the number one most trustworthy company in the healthcare industry by Newsweek in its rankings of the World's Most Trustworthy Companies. This prestigious recognition underscores Cochlear's unwavering commitment to excellence, innovation, and customer-centricity. - Ends - Commercial availability: The new Cochlear™ Nucleus® Nexa™ System will be available in the Boao Lecheng International Medical Tourism Pilot Zone from 20 June 2025 and it will be available in Hong Kong from 16 June 2025. About hearing loss in China According to the World Health Organization (WHO), hearing loss is a major public health issue in China, and its prevalence is expected to increase. The Chinese government has been vigorously promoting the prevention and treatment of hearing loss by establishing and constantly improving the management, technical guidance, and service systems.[2] However, many people with hearing loss still do not seek or receive hearing health care.[2] More than 95 million people in China had moderate-to-complete hearing loss in 2019 according to health estimates.[2] Approximately two in five Chinese people will have hearing loss by 2034 according to health estimate projections.[2] More than 17,000 were born with hearing loss in 2020 according to China CDC data.[8] The Bo'ao Pilot Zones represent critical platforms for Cochlear to introduce cutting-edge hearing solutions, conduct real-world research, and support the development of China's healthcare industry. By aligning with the policies and objectives of these zones, Cochlear remains committed to enhancing the lives of Chinese patients and contributing to the nation's progress in healthcare innovation. About Cochlear Implants Unlike hearing aids which increase the volume of sound, cochlear implants work by enhancing sound clarity, bypassing the damaged part of the ear entirely to stimulate the hearing nerve directly. Cochlear implants focus on enhancing clarity of sound, while hearing aids mostly work by making sounds louder.[9-11] This clarity could help people reclaim their confidence and fully immerse themselves in the meaningful moments of everyday life. About the Cochlear™ Nucleus® Nexa™ System The new system includes the Nucleus Nexa Implant, the Nucleus Kanso® 3 Nexa Sound Processor and the Nucleus 8 Nexa Sound Processor. The Nucleus Nexa Implant and sound processors are supported by Nucleus SmartNav, Nucleus Smart App, Custom Sound® Pro fitting software and wireless accessories. The new Nucleus® Nexa™ System can learn about its user's listening needs and the environment they are in. It can then automatically adjust listening or power management settings to help people hear more clearly[1] or maximise battery life.#* Users can enjoy clearer sound streamed directly from compatible* mobile devices and, in the future, at airports, concert venues and more using Bluetooth® LE Audio and Auracast™ broadcast audio.¥ About Cochlear Limited (ASX: COH) People have always been Cochlear's inspiration, ever since Professor Graeme Clark set out to create the first multi-channel cochlear implant after seeing his father struggle with hearing loss. Since 1981, Cochlear has helped more than 700,000 people in more than 180 countries to hear. As the global leader in implantable hearing solutions, Cochlear connects people with life's opportunities, and welcomes them to the world's largest hearing implant community. Cochlear has a global workforce of more than 5,000 people, with a passion for progress, who strive to meet the needs of people living with hearing loss. The company continually innovates to anticipate future needs, investing more than AUD$3 billion to date in research and development to push the boundaries of technology and help more people hear. www.cochlear.com References and disclaimers Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information. Views expressed are those of the individual. Consult your health professional to determine if you are a candidate for Cochlear technology. D1509691 CI1000 Implant Product Specification. Cochlear Limited; 2023 Aug. H. Wang, Y. Chen, Z. Yang, L. Zhu, Y. Zhao, T. Tian. Estimation and projection of the burden of hearing loss in China: findings from the Global Burden of Disease Study 2019. Public Health, Volume 228, March 2024, Pages 119-127. Published online 13 February 2024. Available at: https://doi.org/10.1016/j.puhe.2024.01.004 Mauger SJ, Warren CD, Knight MR, Goorevich M, Nel E. Clinical evaluation of the Nucleus®6 cochlear implant system: Performance improvements with SmartSound iQ. International Journal of Audiology. 2014 Jul 9;53(8):564–76. Mauger SJ, Jones M, Nel E, Janine Del Dot. Clinical outcomes with the KansoTM off-the-ear cochlear implant sound processor. International Journal of Audiology. 2017 Jan 9;56(4):267–76. Wolfe J, Neumann S, Marsh M, Schafer E, Lianos L, Gilden J, et al. Benefits of Adaptive Signal Processing in a Commercially Available Cochlear Implant Sound Processor. Otology & Neurotology. 2015 Aug;36(7):1181–90. D2182827 Cochlear Nucleus Reliability Report. Cochlear Limited; 2023 Dec. Cochlear. Annual reports [Internet]. Cochlear. 2021. Available from: https://www.cochlear.com/au/en/corporate/investors/annual-reports Zhili Wang, Yunge Gao, Yuzhang Huang, Wenying Nie, Yun Li, Haibin Sheng, Jie Chen, Yuzhu Guo, Kun Han, Zhiwu Huang, Fan Jiang, Jun Zhang, Hao Wu, Ying Chen. Implementation of Universal Newborn Hearing Screening and Analysis of School Enrollment Among Hearing-Impaired Students in China[J]. China CDC Weekly, 2025, 7(9): 312-317. doi: 10.46234/ccdcw2025.050 Fitzpatrick EM, Leblanc S. Exploring the Factors Influencing Discontinued Hearing Aid Use in Patients With Unilateral Cochlear Implants. Trends in Amplification [Internet]. 2010 Dec 1 [cited 2020 Jul 4];14(4):199–210. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111407/ Rumeau C, Frère J, Montaut-Verient B, Lion A, Gauchard G, Parietti-Winkler C. Quality of life and audiologic performance through the ability to phone of cochlear implant users. European Archives of Oto-Rhino-Laryngology. 2014 Dec 20;272(12):3685–92. Runge CL, Henion K, Tarima S, Beiter A, Zwolan TA. Clinical Outcomes of the CochlearTM Nucleus® 5 Cochlear Implant System and SmartSoundTM 2 Signal Processing. Journal of the American Academy of Audiology. 2016 Jun 1;27(6):425–40. ± Smart cochlear implant system is defined as the first and only cochlear implant having Internal memory with upgradeable firmware. # Battery life varies for every user, according to the age of the battery, the programs used each day, your implant type, the thickness of skin covering your implant, and the size and type of battery used. Streaming from compatible devices, True Wireless Devices or FM may decrease sound processor battery life depending on how often and for how long streaming is engaged. * The Cochlear Nucleus 8 Nexa and Nucleus Kanso 3 Nexa sound processors are compatible with Apple and Android devices. For compatibility information and devices visit www.cochlear.com/compatibility ¥ As Bluetooth LE Audio compatible devices become available, a firmware update will be required for you to use certain features. Auracast™ broadcast audio capability is subject to third party adoption of the Auracast protocol. The Bluetooth® and Auracast™ word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Cochlear Limited is under license.
Groundbreaking Technology Empowers Patients to Take Control of Their Health HONG KONG, June 20, 2025 /PRNewswire/ -- Ottai, an Oxford-originated pioneer in AI digital health innovation, today announced the launch of its next-generation AI-powered wearable designed to revolutionize chronic disease management. This breakthrough device continuously monitors key biomarkers, leverages AI for real-time analysis and health log input, enhances patient-device interaction, and delivers personalized lifestyle recommendations. The Ottai biosensor disrupts the paradigm of traditional chronic disease monitoring—characterized by manual input, periodic lab tests, and reactive symptom management—by offering continuous monitoring paired with AI-driven automated and personalized inputs. It integrates deep learning algorithms to analyze vast amounts of real-time biomarker data and health logs, delivering actionable, tailored recommendations. The biosensor also supports intuitive voice-activated commands, allowing users to ask questions and add inputs while receiving real-time, personalized advice. "The Ottai biosensor represents a critical step toward scalable, patient-centric care," said Dr. Calvin Wang, Research Scientist at Ottai. "It represents a new era in healthcare—where we combine biosensing with AI to provide a dynamic and adaptive tool that evolves with patients' health needs and supports long-term disease management." Ottai's biosensor integrates with an AI-powered app to provide real-time glucose monitoring and personalized health insights, empowering users to manage their diabetes effectively. The biosensor uses AI to power a smart health companion that supports users in real time: Real-Time Biomarker Analysis: Track critical health metrics like glucose and detect episodes of hyperglycemia and hypoglycemia continuously. The device is validated against medical gold standards and CE-approved for its accuracy and reliability. Personalized Recommendations: AI algorithms process data to suggest lifestyle, dietary, and activity adjustments, optimizing long-term health outcomes. Voice-Activated Health Logs and Lifestyle Inquiries: Interact with the biosensor via voice commands to effortlessly log health data, dietary and lifestyle habits, personalized questions, receiving real-time, actionable responses. AI-Driven Data Analysis: Advanced machine learning algorithms to analyze complex datasets, that offers users real-time insights into their health trends and risks. Seamless Integration with Other Health Apps: Syncs with other health-tracking platforms such as Apple Health and smartwatches for users' best convenience. About Ottai Ottai is a leader in empowering individuals with actionable insights to prevent and manage chronic conditions. With a mission to make chronic disease management more accessible, personalized, and proactive, Ottai aims to revolutionize the healthcare landscape with advanced, user-friendly solutions. For more information and pricing and availability of Ottai sensors, visit www.ottai.com or contact info@ottai.com , and connect with Ottai on Instagram , and Facebook .
Asclepius AI Table sets a new benchmark for intelligent, hands-on medical learning. TAIPEI, June 20, 2025 /PRNewswire/ -- Surglasses Inc. today announced the launch of the Asclepius AI Table, the world's first anatomy table with fully integrated AI instruction — a groundbreaking device that brings real-time intelligence and immersive interaction into medical and veterinary education. Asclepius AI Table — Where Anatomy Meets Intelligence Unlike traditional systems that rely on external software or passive content, the Asclepius AI Table is a self-contained, AI-enhanced teaching platform. Two built-in digital instructors respond to voice and text in real time, offering guided instruction, anatomical explanations, and adaptive learning based on user input. The system is ready to use out of the box, requiring no technical setup or training, making it ideal for classrooms, labs, and interactive demonstrations. The table features eight deeply integrated modules designed to meet the diverse demands of modern medical and veterinary curricula. Students can freely explore high-resolution 3D virtual cadavers, perform open-ended digital dissection, and examine body structures from any angle. For radiological learning, the table enables ultra-fast 3D reconstruction and visualization of CT scans through a built-in DICOM viewer, with multiple rendering presets for efficient analysis. In the field of pathology, the Histopathology Explorer launches in seconds and includes a large collection of ultra-HD slides, while also supporting custom slide uploads. Movement and biomechanics are covered through the Kinesiology Module, which presents dozens of animated human motion models for understanding joint mechanics and musculoskeletal interactions. Additional tools include CTRender, a powerful engine for importing and manipulating DICOM files; a real-time ultrasound simulator that supports procedural training using clinical data; and a robust veterinary anatomy library with anatomical models for a wide range of species — supporting both human and animal education in a unified environment. The Embryology Timeline rounds out the system, offering a vivid 3D visualization of human development from fertilization to birth — helping students connect macro-level anatomy with developmental biology in a way that textbooks alone cannot achieve. Across all modules, the embedded AI instructors serve as constant companions: answering questions, guiding exploration, and supporting instructors and students alike with precision and immediacy. "The Asclepius AI Table is the first of its kind — an anatomy table that doesn't just show, it teaches," said Dr. Min-Liang Wang, founder and CEO of Surglasses Inc. "By embedding intelligent guidance directly into the table, we're transforming how anatomy and clinical science are taught — making learning faster, deeper, and more intuitive." Now Available for Global Distribution Already generating strong interest from medical schools, teaching hospitals, and veterinary institutions, the Asclepius AI Table is now available worldwide. Surglasses welcomes demo requests, academic partnerships, and distribution inquiries. Media ContactMarketing info@surglasses.comNina nina@surglasses.com www.surglasses.com About Surglasses Inc. Surglasses Inc. develops next-generation solutions for medical training and surgical navigation. Its flagship technologies — including the Caduceus S AR spinal navigation system and the Asclepius AI Table — are redefining how healthcare professionals learn, plan, and perform with greater confidence and clarity.
TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI, a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved AutocathFFR®, the company's non-invasive, AI-driven software solution for evaluating coronary physiology. AutocathFFR® in Action – An AI Powerhouse in the Cath Lab AutocathFFR® is the first fully automated Software as a Medical Device (SaMD) that calculates Fractional Flow Reserve (FFR) values directly from standard X-ray coronary angiograms without the need for guidewires or vasodilatory agents. Generating results in just 37 seconds, the system provides interventional cardiologists with fast, reproducible, and operator-independent decision support in the cath lab. Fractional Flow Reserve (FFR) is a commonly used technique in cardiac catheterization for assessing the extent of blood flow reduction in narrowed coronary arteries. Traditionally, this procedure involves administering a vasodilatory drug to dilate the blood vessels, followed by the insertion of a guidewire equipped with a pressure sensor into the coronary artery. The sensor measures intravascular pressure changes to determine the FFR value, enabling physicians to assess the severity of arterial blockages. AutocathFFR® revolutionizes this standard of care by calculating precise FFR values, fully automatically, directly from routine X-ray coronary angiograms using advanced AI algorithms, eliminating the need for invasive guidewires with a pressure sensor or drug-induced vessel dilation. AutocathFFR® delivers fast, hands-free consistent FFR results in just 37 seconds, empowering cardiologists with precise, reproducible values that minimize operator variability and enhance overall workflow reliability. AI-FFR Pivotal Study The PMDA approval is supported by a multicenter pivotal study that included 504 vessels from patients across six leading hospitals in the United States and Israel. Each patient underwent invasive FFR measurement, which was then compared to AutocathFFR® results analyzed at an independent core laboratory at MedStar Health in Washington, D.C., led by Dr. Hector Garcia. The findings demonstrated a sensitivity of 90.2 percent, specificity of 94.9 percent, and overall diagnostic accuracy of 93.7 percent, validating the system's clinical performance and reliability. Milestone for Japan and for AI in Cardiology The approval coincides with MedHub-AI's strategic partnership with Terumo Corporation, Japan's leading cardiovascular device company. Together the companies will deliver this breakthrough platform across Japan and accelerate adoption of AI driven clinical tools. "This PMDA approval is not only a historic achievement for MedHub AI," said Or Bruch El, CEO of MedHub-AI, "but also a turning point for how AI will shape cardiovascular care moving forward. AutocathFFR® delivers real time, reproducible insights through a fully automated pipeline, enabling physicians to make faster and more confident decisions at the point of care. It is the first end to end AI system in its class to be approved, and we are proud to set this new standard." He added, "The results from our pivotal study give physicians the confidence they need in high stakes and time critical procedures. Our goal is clear. We intend to lead this category without compromise." Next in Pipeline: iFR Pullback and Beyond At the upcoming CVIT conference this July, MedHub-AI will unveil its non invasive iFR pullback solution, expanding its real time physiology suite and moving one step closer to fully wire free coronary assessment. This new capability will allow physicians to visualize pressure gradients along the vessel without the need for invasive tools, enhancing procedural planning and accuracy. In parallel, the company will debut advanced features powered by vision language large models, also known as VLLMs. These AI systems are designed to interpret angiographic images, procedural cues, and patient specific data in real time and offline. By introducing deep contextual understanding directly into the cath lab, VLLMs will support interventional cardiologists with intelligent and dynamic recommendations both during procedures and in post procedural review. This groundbreaking technology is expected to captivate audiences by revealing the full power and potential of the AI powerhouse MedHub-AI is integrating into the heart of interventional cardiology. Toward Global Expansion With PMDA approval now secured in Japan, MedHub-AI is progressing rapidly toward regulatory clearance in the United States. The company is in the final stages of its FDA 510k process and expects approval in the very near future. This next milestone will further accelerate the company's global rollout, bringing its AI powered diagnostic platform to physicians across major healthcare markets worldwide. About MedHub-AI MedHub-AI is redefining the diagnosis of coronary artery disease with AutocathFFR®, the world's leading AI powered, image based FFR solution. By providing fast, reproducible, and non invasive coronary assessments, MedHub-AI enables clinicians to make better informed decisions and is advancing the global shift toward precision medicine in cardiology. AutocathFFR® is built on a proprietary AI framework that allows the platform to continuously improve performance, adapt to new clinical needs, and deliver updated software with greater precision and speed. With regulatory approvals expanding, MedHub-AI is preparing for broad clinical adoption and global commercialization. Contacts:Yarden Bruch-El, COOEmail: Yarden@medhub-ai.com Photo - https://mma.prnasia.com/media2/2714191/MedHub_AutocathFFR.jpg?p=medium600Logo - https://mma.prnasia.com/media2/2147486/5377302/MedHub_logo.jpg?p=medium600
COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a critical need among nurses, who currently spend significant time manually flushing IV-lines to clear residual medication from IV lines. The founding team behind Droplet IV, driving innovation in infusion care. The financing round marks the company's first external investment and includes backing from leading healthcare investors, such as the former executive of ConvaTec, members of experienced MedTech family offices, and seasoned angel investors with nursing and clinical backgrounds. "The clinical relevance of Droplet IV's technology is clear," said John Lindskog, former executive of ConvaTec and Cimon Medical. "It fills a critical gap in IV medication safety and efficiency - a long-overdue solution for hospitals worldwide." Droplet IV's total funding now exceeds $5 million, including more than $3 million in non-dilutive grants and previous funding from the BioInnovation Institute, Europe's leading life science accelerator. The company now has the capital needed to complete its final regulatory and clinical milestones and commercial launch the product in both the European and U.S. markets by 2026. "We get inquiries from nurses regularly asking when they can have the product" said Marcus Bech, CEO of Droplet IV. "This funding will enable us to make it available to our customers already next year, and I am I'm incredibly proud to have attracted investors with such deep expertise and commitment to help us fulfill this mission" Automated IV flushing is gaining increased recognition in clinical settings - especially in areas where accurate medication dosing is critical. Yet no streamlined, automatic solutions currently exist. Nurses are often burdened with time-consuming manual flushing procedures that introduce variability and increase the risk of error. "I'm excited to see Droplet IV speeding up access to this much-needed technology," said Lisa Gorski, a leading U.S.-based Key Opinion Leader (KOL) in IV therapy and Clinical Advisor to Droplet IV. "Nurses need simple, reliable tools to ensure safe and consistent flushing without it becoming a daily burden." The strength of the investor group speaks to both the market's unmet need and the innovation behind Droplet IV's platform. www.DropletIV.com
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
